Fibrogen to present safety and efficacy analyses from roxadustat global phase 3 program at american society of hematology annual meeting

New data show safety and efficacy of roxadustat in treating anemia secondary to lower-risk myelodysplastic syndrome s (mds) regardless of ring sideroblast (rs) or baseline e rythro poietin level

FGEN Ratings Summary

FGEN Quant Ranking